

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{BOX}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Amflee 50 mg spot-on solution

2. STATEMENT OF ACTIVE SUBSTANCES

Each 0.5 ml pipette contains:

fipronil 50 mg

3. PACKAGE SIZE

1 x 0.5 ml
3 x 0.5 ml
6 x 0.5 ml
10 x 0.5 ml
20 x 0.5 ml
30 x 0.5 ml

4. TARGET SPECIES

Cats



5. INDICATIONS

Treatment of fleas and ticks.




Ixodida



Ctenocephalides felis

6. ROUTES OF ADMINISTRATION

Spot-on use.



7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Store in the original container in order to protect from light and moisture. Do not remove from bag until required for use.
The product should be maintained at room temperature (above 14° C) for approximately one hour prior to administration.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto

14. MARKETING AUTHORISATION NUMBERS

Vm 01656/4086

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

{BAG}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Amflee



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES


fipronil 50 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}



KRKA

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

{PIPETTE}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Amflee



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

50 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Amflee 50 mg spot-on solution for cats

2. Composition

Each 0.5 ml pipette contains:

Active substance:

Fipronil 50 mg

Excipients:

Butylhydroxyanisol (E320)	0.10 mg
Butylhydroxytoluene (E321)	0.05 mg
Dimethyl sulfoxide	to 0.50 ml

Light yellow to yellow, clear liquid.

3. Target species

Cats



4. Indications for use

Treatment and prevention of flea (*Ctenocephalides* spp.) and tick (*Dermacentor reticulatus*, *Ixodes ricinus*) infestations in cats.

The product has a persistent insecticidal efficacy for up to 4 weeks against fleas (*Ctenocephalides* spp.) and acaricidal efficacy for up to 4 weeks against *Ixodes ricinus* and for up to 1 week against *Dermacentor reticulatus* and *Rhipicephalus sanguineus*. If *Rhipicephalus sanguineus* ticks are present when the product is applied, all the ticks may not be killed within the first 48 hours but they may be killed within a week.

The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD), where this has been previously diagnosed by a veterinary surgeon.

5. Contraindications

Do not use on kittens less than 2 months old and/or weighing less than 1 kg in the absence of available data.

Do not use in sick (e.g. systemic diseases, fever...) or convalescent animals.

Do not use in rabbits, as adverse reactions and even death could occur.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special warnings:

Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings which should be treated, in case of massive infestation and at the beginning of the control measures, with a suitable insecticide and vacuumed regularly.

The veterinary medicinal product does not prevent ticks from attaching to the animals. If the animal has been treated prior to exposure to the ticks, the tick will be killed in the first 24-48 hours after attachment. This will usually be prior to engorgement, minimising but not excluding the risk of transmission of diseases. Once dead, ticks will often drop off the animal, but any remaining ticks may be removed with a gentle pull.

No data on the effect of bathing/shampooing on the efficacy of the veterinary medicinal product in cats are available. However, based on information available for dogs, weekly immersion in water for one minute reduces the period of persistent insecticidal efficacy against fleas by one week.

For optimal control of flea infestation in a multi-pet household, all animals in the household (e. g. dogs, cats, ferrets, rabbits) should be treated with a suitable insecticide.

When used as part of a strategy for the treatment of Flea Allergy Dermatitis, monthly applications to the allergic patient is recommended and other dogs and cats in the household should be treated with a suitable insecticide.

Special precautions for safe use in the target species:

Avoid contact with the animal's eyes. In the case of accidental eye contact, immediately and thoroughly flush the eyes with water.

Do not apply the veterinary medicinal product on wounds or damaged skin.

It is important to make sure that the veterinary medicinal product is applied to an area where the animal cannot lick it off and to make sure that animals do not lick each other following treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product can cause mucous membrane and eye irritation. Therefore, contact between the veterinary medicinal product and the mouth or eyes should be avoided.

In the case of accidental eye contact, immediately and thoroughly flush the eyes with water. If eye irritation persists seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid contents coming into contact with the fingers. If this occurs, wash off immediately with soap and water.

Wash hands after use.

Do not smoke, drink or eat during application.

People with known hypersensitivity to fipronil or dimethyl sulfoxide or other excipients should avoid contact with the veterinary medicinal product.

Treated animals should not be handled until the application site is dry, and children should not be allowed to play with treated animals until the application site is dry. It is therefore recommended that animals are not treated during the day, but should be treated during the early evening, and that recently treated animals should not be allowed to sleep with owners, especially children.

Keep pipettes in original packaging and dispose of used pipettes immediately.

Pregnancy and lactation:

Laboratory studies have not produced any evidence of teratogenic or embryotoxic effects. Studies have not been carried out with this veterinary medicinal product in pregnant and lactating queens. Use only according to the benefit-risk assessment by the responsible veterinarian.

Overdose:

No adverse effects were observed in target animal safety studies in cats and kittens aged 2 months and older and weighing about 1 kg treated once a month at five times the recommended dose for three consecutive months. The risk of experiencing adverse effects may however increase with overdosing (see section “Adverse events”).

7. Adverse events

Cats:

<p>Very rare (<1 animal / 10,000 animals treated, including isolated reports):</p>	<p>Application site skin squamosis (scaling)¹, Application site alopecia (hair loss)¹, Application site pruritus (itching)¹, Application site erythema (reddening)¹ Generalized itching, Alopecia general (general hair loss) Hypersalivation, Vomiting Neurological signs³, Hyperaesthesia³ Depression³</p>
<p>Undetermined frequency (cannot be estimated from the available data)</p>	<p>Hypersalivation²</p>

¹Transient.

²May be observed for a brief period in the case of licking the administration site.

³Reversible.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Route of administration and dosage:


External use only.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Administer by topical application to the skin 1 pipette of 0.5 ml per animal.

Method of administration:

Remove the pipette from its packaging. Hold the pipette in an upright position, twist and pull the cap off. Turn the cap around and place the other end of the cap back on the pipette. Push and twist the cap to break the seal, then remove the cap from the pipette. Part the coat on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the pipette onto the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot.



9. Advice on correct administration

It is important to make sure that the veterinary medicinal product is applied to an area where the animal cannot lick it off, and to make sure that animals do not lick each other following treatment.

Temporary changes to the coat (clumped/greasy hair and/or deposits on the hair) may be noted at the application site.

For optimal control of flea and/or tick infestation the treatment schedule can be based on the local epidemiological situation.

In the absence of safety studies, the minimum treatment interval is 4 weeks.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in the original container in order to protect from light and moisture. Do not remove from bag until required for use.

The product should be maintained at room temperature (above 14° C) for approximately one hour prior to administration.

Do not use this veterinary medicinal product after the expiry date which is stated on the labels and carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

This veterinary medicinal product should not enter water courses as fipronil may be dangerous for fish and other aquatic organisms.
Do not contaminate ponds, waterways or ditches with the product or empty container. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product not subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 01656/4086

White polypropylene pipette closed with either a polyethylene or polyoxymethylene cap. Each 0.5 ml pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag.

Pack sizes:

Box containing 1, 3, 6, 10, 20 or 30 pipettes.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturer responsible for batch release:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany

Local representatives and contact details to report suspected adverse reactions:

KRKA UK Ltd, United Kingdom, Tel: 02071 646 156, Email: info.uk@krka.biz

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

NFA-VPS

Gavin Hall
Approved: 19 February 2026